Mallinckrodt Plc  (MNK)
Other Ticker:  
Price: $0.3402 $-0.06 -14.971%
Day's High: $0.4102 Week Perf: -39.2 %
Day's Low: $ 0.30 30 Day Perf: -79 %
Volume (M): 543 52 Wk High: $ 11.00
Volume (M$): $ 185 52 Wk Avg: $5.10
Open: $0.40 52 Wk Low: $0.30

 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 13
 Employees 3,600
 Revenues (TTM) (Millions $) 2,266
 Net Income (TTM) (Millions $) -2,841
 Cash Flow (TTM) (Millions $) -1,021
 Capital Exp. (TTM) (Millions $) 45

Mallinckrodt Plc
Mallinckrodt Plc is a specialty pharmaceutical company that develops and manufactures a wide range of medical products used in the treatment of rare and critical diseases.

The company was founded in 1867 and is headquartered in Dublin, Ireland, with its primary commercial offices located in the United States. With a rich history of over 150 years, Mallinckrodt has become a leading provider of medical products and services in the healthcare industry, serving millions of patients worldwide.

The company's pharmaceutical products cover a range of areas, including pain management, autoimmune and rare diseases, respiratory disorders, and central nervous system disorders. Mallinckrodt is known for producing specialty drugs such as Acthar Gel, a drug used in the treatment of autoimmune disorders, and Ofirmev, an intravenous acetaminophen injection used for pain management in hospitals.

In addition to pharmaceutical products, Mallinckrodt also produces medical devices and diagnostics tools. The company's medical devices line includes products such as surgical instruments, single-use catheters, and implantable devices for spine and orthopedics. Its diagnostics business offers various imaging agents and injectable dyes used in radiology and cardiology procedures.

Mallinckrodt's operations span over 40 countries, with manufacturing facilities located in the Americas, Europe, and Asia. The company employs over 4,500 people and maintains strong partnerships with healthcare providers and researchers.

Mallinckrodt has a strong commitment to social responsibility and sustainability. The company has implemented green initiatives to reduce its environmental footprint, such as carbon emissions reduction targets, waste diversion programs, and water conservation efforts. Furthermore, the company supports various community outreach programs, including those focused on education, health, and the environment.

Overall, Mallinckrodt is a reputable and innovative pharmaceutical company known for its high-quality products and commitment to improving patient care. Its dedication to social responsibility and sustainability has also garnered the company a positive reputation in the healthcare industry.

   Company Address: College Business & Technology Park Dublin 15
   Company Phone Number: 696 0000   Stock Exchange / Ticker: MNK
   MNK is expected to report next financial results on March 02, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators

As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.

Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry

In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.

Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.

Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

Onconova Therapeutics Inc (ONTX) has recently reported its fiscal third-quarter results for 2023, and the numbers are not looking promising for the biopharmaceutical company. The company's financials reveal a decrease in earnings per share (EPS) compared to the same quarter last year, as well as a surge in deficit from the previous quarter.
For the fiscal third quarter of 2023, ONTX reported a loss of $-0.23 per share, which is slightly better than the loss of $-0.26 per share reported a year ago. However, compared to the previous quarter, the deficit has increased from $-0.20 per share. This indicates a concerning trend of worsening financial performance for the company.


Mallinckrodt Plc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com